

14th February, 2018

To

The Department of Corporate Services
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400001.

Dear Sir,

Sub: Outcome of Board Meeting held on 14th February, 2018 – Regulation 30 of SEBI
(Listing Obligation and Disclosure Requirements) (LODR) Regulations, 2015

Ref: Scrip Code: 526301

With reference to the above cited subject, we would like to inform you that the Board of Directors of the Company in their meeting held on 14th February, 2018, have inter-alia:


1. Considered and approved the un-audited financial results (both Standalone and Consolidated) for the 3rd quarter ended 31st December, 2018 for the said period and took note of the limited review report of Statutory Auditors on the same. The board meeting started at 11.30 a.m. concluded at 3.30 p.m.

This is for your information and records,

Thanking you,

Yours faithfully,

For Medinova Diagnostic Services Limited


Y.K.Priyadarshini
Company Secretary



14th February, 2018 ✓

To

The Department of Corporate Services
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001.

Dear Sir/Madam,

Sub: Submission of un-audited financial results under Regulation 33 of SEBI (LODR) Regulations, 2015 for the 3rd quarter ended 31st December, 2017 and limited review report of statutory auditors thereon.

Ref: Scrip Code: 526301

With reference to the above, we would like to inform you that the Board of Directors of the Company at their meeting held on 14th February, 2018 inter-alia:

- Considered and approved the un-audited financial results (both Standalone and Consolidated) for the 3rd quarter ended 31st December, 2017, as required under Regulation 33 of SEBI (LODR) Regulations, 2015 and took note of the limited review report of auditors on these results.

Hence, please find the following documents that are required to be submitted under Regulation 33 of SEBI (LODR) Regulations, 2015/ SEBI Circulars in this regard:

- a) The un-audited financial results (both Standalone and consolidated) for the 3rd quarter ended 31st December, 2017.
- b) Limited review report of Statutory auditors (both Standalone and consolidated).

The aforesaid results, duly reviewed by the Audit Committee, have been approved and taken on record by the Board of Directors at Board Meeting held today i.e. on 14th February, 2018.

This is for your information and records.

Thanking you

For Medinova Diagnostic Services Limited

Y.K. Priyadarshini

Y.K.Priyadarshini
Company Secretary



UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2017

(Rs. in Lakhs)

Sl. No.	Particulars	Quarter ended 31.12.2017 (Unaudited)	Quarter ended 30.09.2017 (Unaudited)	Quarter ended 31.12.2016 (Unaudited)	Nine Months ended 31.12.2017 (Unaudited)	Nine Months ended 31.12.2016 (Unaudited)	Year ended 31.03.2017 (Audited)
1	Income:						
	(a) Revenue from operations	170.78	166.87	137.27	492.73	459.96	600.85
	(b) Other Income	1.82	1.84	2.00	5.56	19.11	21.28
	Total Income	172.60	168.71	139.27	498.29	479.07	622.13
2	Expenses						
	(a) Cost of Material Consumed	29.81	34.86	20.91	90.35	73.46	98.32
	(b) Employees benefit Expense	49.78	51.58	48.27	149.13	156.15	204.29
	(c) Finance Costs	12.05	12.31	15.08	36.47	44.93	61.78
	(d) Depreciation & Amortisation Expenses	20.67	22.82	31.37	66.88	93.69	124.90
	(e) Other Expenses	76.65	91.30	92.31	272.61	265.78	368.95
	Total Expenses	188.96	212.87	207.94	615.44	634.01	858.24
3	Profit / (Loss) before Exceptional and Extraordinary items and Tax (1-2)	(16.36)	(44.16)	(68.67)	(117.15)	(154.94)	(236.11)
4	Exceptional Items	0.00	0.00	0.00	0.00	0.00	162.57
5	Profit / (Loss) before Extraordinary items and Tax (3+4)	(16.36)	(44.16)	(68.67)	(117.15)	(154.94)	(73.54)
6	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit / (Loss) before Tax (5-6)	(16.36)	(44.16)	(68.67)	(117.15)	(154.94)	(73.54)
8	Tax Expenses						
	(a) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Deferred Tax	0.00	0.00	0.00	0.00	0.00	(11.98)
9	Profit / (Loss) for the period (7-8)	(16.36)	(44.16)	(68.67)	(117.15)	(154.94)	(61.56)
10	Other Comprehensive income	0.00	0.00	0.00	0.00	0.00	0.00
11	Total Comprehensive income for the period (9+10)	(16.36)	(44.16)	(68.67)	(117.15)	(154.94)	(61.56)
12	Paid-up Equity Share capital (Face Value Rs 10/- per share)	995.68	995.68	945.68	995.68	945.68	995.68
13	Earnings per Equity Share						
	a) Basic (Rs.)	(0.16)	(0.44)	(0.73)	(1.17)	(1.64)	(0.61)
	b) Diluted (Rs.)	(0.16)	(0.44)	(0.73)	(1.17)	(1.64)	(0.61)

Notes to Standalone Financial Results for the Quarter Ended 31.12.2017

- The Company has adopted Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder from 01st April 2017. These results have been prepared in accordance with recognition and measurement principles laid down in IND AS 34 on Interim Financial Reporting and Other accounting principles generally accepted in India. The figures for the Quarter and Nine Months ended 31st December, 2017 presented here are also IND AS compliant.
- The above results were reviewed by the audit committee and thereafter taken on record by the Board of Directors at its meeting held on 14th February, 2018 and also limited review was carried out by the Statutory Auditors.
- As the company business activity falls within a single primary business segment (viz Diagnostic Services) the disclosure requirements of Accounting Standard (AS-108) "Operating Segments" issued by the Institute of Chartered Accountants of India are not applicable.
- The impact of deferred tax will be determined and provided at the year end as per the company's consistently followed practice.

Contd...2

:: 2 ::

5. Reconciliation between results previously reported under erstwhile Indian GAAP and as presented now under IND AS.

(Rs. in Lakhs)

Description	Quarter Ended 31.12.2016	Nine Months Ended 31.12.2016	Financial year ended 31.03.2017
	Unaudited		Audited
Net profit under previous GAAP	-68.67	-154.94	-61.56
Adjustments	-	-	-
Net Profit as per IND AS	-68.67	-154.94	-61.56

6 Figures for the previous periods have been regrouped /rearranged wherever necessary.

for MEDINOVA DIAGNOSTIC SERVICES LTD.

Place : Hyderabad
Date : 14.02.2018



Sunil Chandra Kondapally
SUNIL CHANDRA KONDAPALLY
MANAGING DIRECTOR
DIN 01409332



Limited Review Report on Unaudited Standalone Financial Results

Review Report

To the Board of Directors

Medinova Diagnostic Services Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Medinova Diagnostic Service Limited ("the company") for the quarter and nine months ended 31st December 2017, ("the Statement") being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular. No. CIR/CFD/FAC/62/2016 dated 5th July, 2016.
2. This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular CIR/CFD/FAC/62/2016 dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ratnam Dhaveji & Co
Chartered Accountants
Firm Regn No 0066775



C V Ratnam Dhaveji
C V Ratnam Dhaveji
Partner
M.No 203479

Hyderabad
14.02.2018


UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2017

(Rs. in Lakhs)

Sl. No.	Particulars	Quarter ended 31.12.2017 (Unaudited)	Quarter ended 30.09.2017 (Unaudited)	Quarter ended 31.12.2016 (Unaudited)	Nine Months ended 31.12.2017 (Unaudited)	Nine Months ended 31.12.2016 (Unaudited)	Year ended 31.03.2017 (Audited)
1	Income:						
	(a) Revenue from operations	230.16	216.66	178.31	641.57	602.35	779.15
	(b) Other Income	0.02	0.04	0.25	0.16	13.76	14.13
	Total Income	230.18	216.70	178.56	641.73	616.11	793.28
2	Expenses						
	(a) Cost of Material Consumed	35.57	36.92	23.90	100.78	84.25	112.86
	(b) Employees benefit Expense	53.13	54.72	51.54	157.96	166.66	218.42
	(c) Finance Costs	20.50	20.94	25.14	63.00	76.77	103.94
	(d) Depreciation & Amortisation Expenses	45.70	47.84	66.27	141.69	198.00	263.34
	(e) Other Expenses	98.76	111.78	113.96	333.55	320.03	442.69
	Total Expenses	253.66	272.20	280.81	796.98	845.71	1,141.25
3	Profit / (Loss) before Exceptional and Extraordinary items and Tax (1-2)	(23.48)	(55.50)	(102.25)	(155.25)	(229.60)	(347.97)
4	Exceptional Items	0.00	0.00	0.00	0.00	0.00	162.57
5	Profit / (Loss) before Extraordinary items and Tax (3+4)	(23.48)	(55.50)	(102.25)	(155.25)	(229.60)	(185.40)
6	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit / (Loss) before Tax (5-6)	(23.48)	(55.50)	(102.25)	(155.25)	(229.60)	(185.40)
8	Tax Expenses						
	(a) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Deferred Tax	0.00	0.00	0.00	0.00	0.00	(10.54)
9	Profit / (Loss) for the period (7-8)	(23.48)	(55.50)	(102.25)	(155.25)	(229.60)	(174.86)
10	Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	0.00
11	Total Comprehensive income for the period (9-10)	(23.48)	(55.50)	(102.25)	(155.25)	(229.60)	(174.86)
	Net Profit attributable to:						
	(a) Owners of the Company	(23.48)	(45.50)	(90.50)	(132.25)	(203.47)	(129.20)
	(b) Non Controlling Interest	0.00	(10.00)	(11.75)	(23.00)	(26.13)	(45.66)
	Other Comprehensive Income attributable to:						
	(a) Owners of the Company	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Non Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00
	Total Comprehensive Income attributable to:						
	(a) Owners of the Company	(23.48)	(45.50)	(90.50)	(132.25)	(203.47)	(129.20)
	(b) Non Controlling Interest	0.00	(10.00)	(11.75)	(23.00)	(26.13)	(45.66)
12	Paid-up Equity Share capital (Face Value Rs 10/- per share)	995.68	995.68	945.68	995.68	945.68	995.68
13	Earnings per Equity Share						
	a) Basic (Rs.)	(0.23)	(0.46)	(0.96)	(1.32)	(2.15)	(1.29)
	b) Diluted (Rs.)	(0.23)	(0.46)	(0.96)	(1.32)	(2.15)	(1.29)

Notes to Consolidated Financial Results for the Quarter Ended 31.12.2017

1. The Company has adopted Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder from 01st April 2017. These results have been prepared in accordance with recognition and measurement principles laid down in IND AS 34 on Interim Financial Reporting and Other accounting principles generally accepted in India. The figures for the Quarter and Nine Months ended 31st December, 2017 presented here are also IND AS compliant.



Contd....2

2. The above results were reviewed by the audit committee and thereafter taken on record by the Board of Directors at its meeting held on 14th February, 2018 and also limited review was carried out by the Statutory Auditors.
3. As the company business activity falls within a single primary business segment (viz Diagnostic Services) the disclosure requirements of Accounting Standard (AS-108) "Operating Segments" issued by the Institute of Chartered Accountants of India are not applicable.
4. The impact of deferred tax will be determined and provided at the year end as per the company's consistently followed practice.
5. Reconciliation between results previously reported under erstwhile Indian GAAP and as presented now under IND AS.


(Rs. in Lakhs)

Description	Quarter Ended	Nine Months Ended	Financial Year Ended
	31.12.2016	31.12.2016	31.03.2017
	Unaudited		Audited
Net profit under previous GAAP	-102.25	-229.60	-174.86
Adjustments	-	-	-
Net Profit as per IND AS	-102.25	-229.60	-174.86

6. Figures for the previous periods have been regrouped /rearranged wherever necessary.

for MEDINOVA DIAGNOSTIC SERVICES LTD.




SUNIL CHANDRA KONDAPALLY
MANAGING DIRECTOR
DIN 01409332

Place : Hyderabad

Date : 14.02.2018



Limited Review Report on Unaudited Consolidated Financial Results

Review Report
To the Board of Directors
Medinova Diagnostic Services Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Medinova Diagnostic Services Limited ("the company") its subsidiary LLP (together referred to as the "Group") for the quarter and nine months period ended 31st December 2017, ("the Statement") being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular CIR/CFD/FAC/62/2016 dated 5th July, 2016.
2. This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. The Statement includes the results of the following entities:

S. No	Name of the Entity	
1.	Medinova Diagnostic Services Limited	(The Parent)
2.	Medinova Millennium MRI Services LLP	(The Subsidiary LLP)
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ratnam Dhaveji & Co
Chartered Accountants
Firm Regn No 0066775



[Signature]
C V Ratnam Dhaveji
Partner
M.No 203479

Hyderabad
14.02.2018